MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202527090372 A) filed by Chengdu Zenitar Biomedical Technology Co. Ltd., Sichuan, China, on Sept. 22, for 'triazine compound and use thereof.'
Inventor(s) include Chen, Lijuan; Wang, Taijin; Jia, Tao; and Li, Gang.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "Disclosed in the present invention are a triazine compound and the use thereof, which belong to the technical field of chemical medicine. The triazine compound as represented by formula (I) provided in the present invention can be used as an NLRP3 inhibitor, has high activity and good pharmacokinetic properties, and provides a new approach for treating NLRP3-related diseases."
The patent application was internationally filed on Mar. 22, 2024, under International application No.PCT/CN2024/083349.
Disclaimer: Curated by HT Syndication.
